COVID-19: the epidemiology and treatment

Qu, Liujing; Li, Jinchun; Ren, Hao

doi:10.12968/hmed.2020.0580

Cited by 11 publications

(3 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Oseltamivir is a neuraminidase inhibitor approved by FDA for influenza (8). Neuraminidase protein is not encoded by SARS-CoV-2 (9). However, Oseltamivir can bind effectively to the active site of key proteins in SARS-CoV-2, which makes it beneficial against COVID-19 (7).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial

Elgohary

Hasan

Ibrahim

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to HCV in the replication process. Sofosbuvir/ledipasvir is an approved drug by the FDA to treat HCV infection. This study investigates the efficacy of Sofosbuvir/ledipasvir as a treatment for patients with moderate COVID-19 infection.. Methods: This is a single-blinded parallel-randomized controlled trial. The participants were randomized equally into the intervention group received Sofosbuvir/ledipasvir (S.L. group), and the control group received Oseltamivir, Hydroxychloroquine, and Azithromycin (OCH group). The primary outcomes were the cure rate over time and the incidence of serious adverse events. The secondary outcomes included the laboratory findings. Results: Two hundred and fifty patients were divided equally into each group. Both groups were similar regarding gender, but age was higher in the S.L. group (p=0.001). In the S.L. group, 89 (71.2%) patients were cured, while only 51 (40.8%) patients were cured in the OCH group. The cure rate was significantly higher in the S.L. group (RR=1.75, p<0.001). Kaplan-Meir plot showed a considerably higher cure over time in the S.L. group (Log-rank test, p=0.032). There were no deaths in the S.L. group, but there were six deaths (4.8%) in the OCH group (RR=0.08, p=0.013). Seven patients (5.6%) in the S.L. group and six patients (4.8%) in the OCH group were admitted to ICU (RR=1.17, P=0.776). There was no significant difference between treatment groups regarding Total Leukocyte Count, Neutrophils count, Lymph, Alanine transaminase, and Urea. Conclusion: Sofosbuvir/ledipasvir is suggestive of being effective in treating patients with moderate COVID-19 infection. Further studies are needed to compare Sofosbuvir/ledipasvir with the new treatment protocols.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial

Elgohary

Hasan

Ibrahim

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Oseltamivir is a neuraminidase inhibitor approved by the FDA for influenza [ 8 ]. Neuraminidase protein is not encoded by SARS-CoV-2 [ 9 ]. However, Oseltamivir can bind effectively to the active site of key proteins in SARS-CoV-2, which makes it beneficial against COVID-19 [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial

et al. 2022

View full text Add to dashboard Cite

COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is an approved drug to treat HCV infection. This study investigates the efficacy of Sofosbuvir/ledipasvir as a treatment for patients with moderate COVID-19 infection. This is a single-blinded parallel-randomized controlled trial. The participants were randomized equally into the intervention group that received Sofosbuvir/ledipasvir (S.L. group), and the control group received Oseltamivir, Hydroxychloroquine, and Azithromycin (OCH group). The primary outcomes were the cure rate over time and the incidence of serious adverse events. The secondary outcomes included the laboratory findings. 250 patients were divided equally into each group. Both groups were similar regarding gender, but age was higher in the S.L. group (p=0.001). In the S.L. group, 89 (71.2%) patients were cured, while only 51 (40.8%) patients were cured in the OCH group. The cure rate was significantly higher in the S.L. group (RR=1.75, p<0.001). Kaplan-Meir plot showed a considerably higher cure over time in the S.L. group (Log-rank test, p=0.032). There were no deaths in the S.L. group, but there were six deaths (4.8%) in the OCH group (RR=0.08, p=0.013). Seven patients (5.6%) in the S.L. group and six patients (4.8%) in the OCH group were admitted to the intensive care unit (ICU) (RR=1.17, P=0.776). There were no significant differences between treatment groups regarding total leukocyte and neutrophils count, lymph, and urea. Sofosbuvir/ledipasvir is suggestive of being effective in treating patients with moderate COVID-19 infection. Further studies are needed to compare Sofosbuvir/ledipasvir with new treatment protocols.

show abstract

“…Вступ. Коронавірусне захворювання 2019 року (COVID-19) залишається серйозною загрозою стану громадського здоров'я як на сьогодні, так і в майбутньому [1,2]. Вірус ушкоджує майже всі системи й органи, але найбільшого ураження зазнають легені [3].…”

unclassified

Modeling of experimental acute bronchopneumonia with pulmonary fibrosis

Ziablitsev¹

2021

Eksp.klin.fiziol.biohim.

View full text Add to dashboard Cite

На даний час існує нагальна потреба в створенні доступної експериментальної моделі для відтворення основних патогенетичних механізмів COVID-асоційованого ушкодження легень. Мета роботи -розробити модель експериментальної гострої бронхопневмонії з розвитком фіброзу легень. Групі лабораторних щурів лінії Вістар (n = 20) з повним дотриманням біоетичних норм під тіопенталовим знеболюванням було проведене оперативне втручання з уведенням у трахею стерильної капронової нитки довжиною 2,5 см та товщиною 0,2 мм на глибину 2,5 см. У контрольну групу увійшло 5 тварин. Упродовж 28 діб тварин спостерігали, робили патоморфологічні, цитологічні, гематологічні та мікроскопічні дослідження. Протягом спостереження наростав ціаноз, дихання утруднювалося з активним залученням дихальних м'язів, вислуховувалися виражені хрипи, крепітація. Ректальна температура збільшувалася на 1-1,5 о С. На секційному дослідженні через 7 діб легені були набряклими, блідо-рожевого кольору, мали нашарування фібрину, виражений ціаноз, внутрішньотканинні геморагії. Через 21 добу ці зміни доповнювалися розвитком ателектазу та фіброзу. На 21-й день збільшувався гранулоцитарно-лімфоцитарний індекс (у 1,5 разу; р = 0,003). Мікроскопічне дослідження показало розвиток на першому тижні гострого ексудативного бронхолегеневого запалення, на другому -формування перибронхіальних та альвеолярних абсцесів, з їх організацією на третьому тижні з подальшим розвитком дифузного фіброзу паренхіми та гіалінозу судин.Модель гострої аспираційної бронхопневмонії у щурів з уведенням капронової нитки у трахею дає змогу отримати основні клінічні та морфологічні прояви гострого ексудативно-проліферативного пошкодження легень з розвитком фіброзу легеневої тканини.

show abstract

COVID-19: the epidemiology and treatment

Cited by 11 publications

References 63 publications

Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial

Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial

Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial

Modeling of experimental acute bronchopneumonia with pulmonary fibrosis

Contact Info

Product

Resources

About